Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation

Copland, M. , Walker, I.D. and Tait, R.C. (2001) Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Archives of Internal Medicine, 161(17), pp. 2125-2128. (doi: 10.1001/archinte.161.17.2125)

Full text not currently available from Enlighten.

Abstract

Background: Warfarin sodium therapy in patients with atrial fibrillation markedly reduces the incidence of embolic stroke. However, in elderly patients warfarin therapy is often underused owing to the perceived higher risk of hemorrhagic complications. Objectives: To assess the quality of anticoagulant control and the incidence of hemorrhagic complications and stroke in an elderly population (> 75 years old) compared with a younger control group (between 60 and 69 years) and to assess the quality of anticoagulant control and incidence of hemorrhagic complications in those patients who recently commenced receiving warfarin therapy (first year of therapy). Patients and Methods: In this retrospective follow-up study, anticoagulant control and the incidence of hemorrhagic complications and stroke were assessed in an elderly population (> 75 years old) compared with a younger control group (between 60 and 69 years), all with atrial fibrillation(target international normalized ratio [INR] 2.5) and attending a hospital outpatient anticoagulant clinic. Results: A total of 328 patients were studied over a 21-month period. There were 204 patients in the control group providing 288 patient-years of follow-up and 124 patients in the elderly group providing 170 patient-years of follow-up. The percentage of INR results in the target range was not statistically significantly different between the elderly and control groups (71.5% vs 66.1%) and the occurrences of incidences of INR greater than 7 were 4.2% in the control group and 4.7% in the elderly group (P=.96). The incidences of major hemorrhage were 2.8% per year in the elderly group and 2.9% per year in the control group (P=.96); overall incidence was 2.8% (95% confidence interval, 1.3%-4.4%). One hundred one of the 328 patients studied commenced warfarin therapy during or within 3 months of the start of the study. In this induction group, 62.1% of INRs were within the target range compared with 70.9% of INRs in patients who had been receiving warfarin therapy for more than 3 months at the start of the study (P=.002). The incidences of INR greater than 7 and major hemorrhage were 7.9% per year and 6.9% per year, respectively, in the cohort who recently began warfarin therapy compared with 3.4% per year and 1.7% per year in the group who were receiving warfarin therapy for more than 3 months. Conclusion: While it was impossible to consider any selection bias at the level of referral to the clinic, these findings suggest that the elderly population attending our anticoagulant clinic did not have poorer anticoagulant control or an increased incidence of hemorrhage while receiving warfarin therapy.

Item Type:Articles
Additional Information:Annual Scientific Meeting of the West-of-Scotland-Blood-Club GLASGOW, SCOTLAND, MAY 24, 2000, W Scotland Blood Club
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi
Authors: Copland, M., Walker, I.D., and Tait, R.C.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Archives of Internal Medicine
ISSN:0003-9926

University Staff: Request a correction | Enlighten Editors: Update this record